Experienced in Factor 7 Deficiency

Dr. Han W. Tun

Hematology Oncology | Hematology | Oncology
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
Accepting New Patients
Offers Telehealth
Experienced in Factor 7 Deficiency
Mayo Clinic Jacksonville
4500 San Pablo Rd S, 
Jacksonville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Han Tun is a Hematologist Oncology specialist and a Hematologist in Jacksonville, Florida. Dr. Tun is rated as an Experienced provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Tun is currently accepting new patients.

His clinical research consists of co-authoring 110 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Factor 7 Deficiency.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Mayo Clinic
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

MAYO CLINIC JACKSONVILLE
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 1
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase II Expansion Cohorts Studies of a Novel Triple Combination Therapy, DTRM-555, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
A Phase 1 Trial to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Drug: Tinostamustine
Study Phase: Phase 1
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2024
Intervention Type: Biological, Drug, Other
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Lenalidomide, Rituximab
Study Phase: Phase 1/Phase 2
Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Enrollment Status: Completed
Publish Date: January 06, 2023
Intervention Type: Drug, Biological
Study Drugs: Nivolumab, Pomalidomide
Study Phase: Phase 1
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Biological, Drug, Other
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

110 Total Publications

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study.
Journal: EClinicalMedicine
Published: May 06, 2025
Similar Doctors
Advanced in Factor 7 Deficiency
Dr. Daniel A. Kobrinski
Hematology Oncology | Oncology | Hematology
Advanced in Factor 7 Deficiency
Dr. Daniel A. Kobrinski
Hematology Oncology | Oncology | Hematology

Cancer Specialists LLC

700 3rd St, Suite 302, 
Neptune Beach, FL 
 (4.6 miles away)
904-997-3800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Kobrinski is a Hematologist Oncology specialist and an Oncologist in Neptune Beach, Florida. Dr. Kobrinski is rated as a Distinguished provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, and Breast Cancer. Dr. Kobrinski is currently accepting new patients.

Advanced in Factor 7 Deficiency
Dr. Marc A. Warmuth
Hematology Oncology | Hematology | Oncology
Advanced in Factor 7 Deficiency
Dr. Marc A. Warmuth
Hematology Oncology | Hematology | Oncology

Cancer Specialists LLC

121 Whitehall Dr, 
St Augustine, FL 
 (35.3 miles away)
904-825-4500
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Warmuth is a Hematologist Oncology specialist and a Hematologist in St Augustine, Florida. Dr. Warmuth is rated as a Distinguished provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Warmuth is currently accepting new patients.

Experienced in Factor 7 Deficiency
Dr. Suprith Badarinath
Hematology Oncology | Hematology | Oncology
Experienced in Factor 7 Deficiency
Dr. Suprith Badarinath
Hematology Oncology | Hematology | Oncology

Cancer Specialists LLC

1658 St Vincent's Way, 230 Cancer Specialist Of N, 
Middleburg, FL 
 (25.8 miles away)
904-214-8050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suprith Badarinath is a Hematologist Oncology specialist and a Hematologist in Middleburg, Florida. Dr. Badarinath is rated as a Distinguished provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Colorectal Cancer, and Paget Disease of the Breast. Dr. Badarinath is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tun's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 13 Advanced Conditions
View All 116 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile